Showing 19,961 - 19,980 results of 100,215 for search '(( 5 ng decrease ) OR ( 5 ((nn decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.53s Refine Results
  1. 19961

    S2 Data - by Angga Yudaputra (16792924)

    Published 2023
    “…We proposed the category CR B1ab(iii,v), C2a(ii) as the new conservation status of <i>N</i>. …”
  2. 19962
  3. 19963
  4. 19964
  5. 19965
  6. 19966
  7. 19967
  8. 19968
  9. 19969
  10. 19970
  11. 19971
  12. 19972
  13. 19973
  14. 19974
  15. 19975
  16. 19976
  17. 19977

    DataSheet_1_A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.docx by Jiawen Zhang (586977)

    Published 2021
    “…In vitro, carvedilol decreased TLR2 expression in RAW 264.7 cells, further reducing KLK5 secretion and LL-37 expression and ultimately inhibiting rosacea-like inflammatory reactions. …”
  18. 19978

    DataSheet_1_A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.docx by Jiawen Zhang (586977)

    Published 2022
    “…In vitro, carvedilol decreased TLR2 expression in RAW 264.7 cells, further reducing KLK5 secretion and LL-37 expression and ultimately inhibiting rosacea-like inflammatory reactions. …”
  19. 19979

    DataSheet_2_A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.docx by Jiawen Zhang (586977)

    Published 2022
    “…In vitro, carvedilol decreased TLR2 expression in RAW 264.7 cells, further reducing KLK5 secretion and LL-37 expression and ultimately inhibiting rosacea-like inflammatory reactions. …”
  20. 19980

    DataSheet_2_A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.docx by Jiawen Zhang (586977)

    Published 2021
    “…In vitro, carvedilol decreased TLR2 expression in RAW 264.7 cells, further reducing KLK5 secretion and LL-37 expression and ultimately inhibiting rosacea-like inflammatory reactions. …”